| Dr Duried Mawaheb Kassab, DO | |
|
12250 E Iliff Ave, #300, Aurora, CO 80014-6318 | |
| (720) 524-1550 | |
| (720) 524-1551 |
| Full Name | Dr Duried Mawaheb Kassab |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 12250 E Iliff Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386818342 | NPI | - | NPPES |
| 14824779 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 49036 (Colorado) | Secondary |
| 207Q00000X | Family Medicine | DR.0049036 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Hospice | Minneapolis, MN | Hospice |
| Seasons Hospice And Palliative Care Of Colorado Ll | Westminster, CO | Hospice |
| Seasons Hospice Palliative Care | West allis, WI | Hospice |
| Hca-healthone Dba Swedish Medical Center | Englewood, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inpatient Consultants Of Colorado Pc | 6204748452 | 6 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Entity Name | Inpatient Consultants Of Colorado Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720184690 PECOS PAC ID: 6204748452 Enrollment ID: O20031105000227 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Entity Name | Portercare Adventist Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760761928 PECOS PAC ID: 0941110886 Enrollment ID: O20090115000327 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Entity Name | Colorado Post-acute Medical Services 1 Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245779727 PECOS PAC ID: 1153698634 Enrollment ID: O20170605002342 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Entity Name | Co Pacs 2 Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154807055 PECOS PAC ID: 4880943596 Enrollment ID: O20180814000694 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Entity Name | Seasons Medical Group Of Colorado Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649707332 PECOS PAC ID: 7810327285 Enrollment ID: O20200427000941 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Duried Mawaheb Kassab, DO 12250 E Iliff Ave, #300, Aurora, CO 80014-6318 Ph: (720) 524-1550 | Dr Duried Mawaheb Kassab, DO 12250 E Iliff Ave, #300, Aurora, CO 80014-6318 Ph: (720) 524-1550 |
News Archive
Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and six-month period ended June 30, 2011.
GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.
› Verified 1 days ago
Heather Brougham, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Dr. Marcus Ian Ng, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 16290 E Quincy Ave, Aurora, CO 80015 Phone: 303-338-4545 | |
Dr. Vanessa Rosalie Herring, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12631 E 17th Ave Ste F496, Aurora, CO 80045 Phone: 303-724-9700 | |
Kayley Swope, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Betty Mabel Martinez, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 13701 E Mississippi Ave, Suite 200, Aurora, CO 80012 Phone: 303-398-6340 | |
Stephen Loyd, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 303-493-7000 | |
Dr. Daniel Hurtt, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 275 S Aspen St, Aurora, CO 80011 Phone: 720-847-7658 Fax: 720-847-7480 |